Related Experiment Video

Updated: Sep 28, 2026

Enhancement of Facial Rejuvenation Through a Combination of 1565 nm Non-Ablative Fractional Laser with 30% Supramolecular Salicylic Acid
03:47

Enhancement of Facial Rejuvenation Through a Combination of 1565 nm Non-Ablative Fractional Laser with 30% Supramolecular Salicylic Acid

Published on: September 27, 2024

[Acetylsalicylic acid (ASA)--is everything clear?]

J Spinar1, J Vítovec

  • 1II. interní klinika FN u sv. Anny a Lékarské fakulty MU, Brno.

Vnitrni Lekarstvi
|November 12, 2002
PubMed

Insights

Acetylsalicylic acid (ASA) use in heart conditions is common, but long-term mortality benefits remain unproven. Lower ASA doses (≤100 mg) appear safer and may reduce mortality in ischemic heart disease and heart failure.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Acetylsalicylic acid (ASA) is frequently prescribed for ischemic heart disease (IHD) and chronic heart failure.
  • Evidence for ASA's long-term mortality benefit in these conditions is limited.

Purpose:

  • To review current evidence on ASA's efficacy and safety in IHD and heart failure.
  • To discuss potential interactions with ACE inhibitors and compare ASA with other antiplatelet agents.

Summary:

  • While ASA reduces mortality in acute coronary syndrome, long-term benefits in IHD and heart failure require further investigation.
  • Higher ASA doses (>300 mg) increase complications without proven mortality benefit, whereas lower doses (≤100 mg) show promise for reducing total mortality.
  • Potential weakening of ACE inhibitors when co-administered with ASA in heart failure warrants consideration.

Impact:

  • Highlights the need for evidence-based prescribing of ASA in cardiovascular patients.
  • Informs clinical decisions regarding optimal ASA dosage and potential drug interactions.
  • Suggests lower ASA doses may be a safer and effective strategy for managing IHD and heart failure.

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
SBAR II: Application of SBAR01:14

SBAR II: Application of SBAR

SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also promote...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...